Navigation Links
Mylan Announces Clarinex(R) Settlement Agreement
Date:4/8/2009

PITTSBURGH, April 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced the settlement of all patent litigation relating to Desloratadine Tablets, 5 mg, the generic version of Schering- Plough's Clarinex(R) allergy medication. This litigation has been pending in the U.S. District Court of New Jersey since September 2006.

Pursuant to the settlement, Mylan will have the right to market Desloratadine Tablets, 5 mg, in the U.S. on July 1, 2012, or earlier in certain circumstances, provided that the U.S. Food and Drug Administration (FDA) approves Mylan's abbreviated new drug application (ANDA). Mylan's product may be the prescription form or an over-the-counter version, depending on the status of Clarinex at the time. Additional terms of the settlement are confidential, and the agreement is subject to review by the Department of Justice and the Federal Trade Commission.

Desloratadine Tablets, 5 mg, had U.S. sales of approximately $284 million for the 12 months ending Dec. 31, 2008, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
2. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
4. Mylan Announces Transition of Chief Financial Officer
5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
6. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
10. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
11. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing platform ... with the 2017 Women’s Choice Award. The identification by women of an effective ... 4 migraine sufferers are women. In a survey taken by the Women’s Choice Award ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Each of the past six years, Lightning Labels ... pictures of these labels and stickers, demonstrating the variety and creativity of their designs. Submissions ... label images came in. Now, it's time to announce the winners of the sixth annual ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: ... a B17 bomber named Edward Koontz. “To Walk Away” is the creation of published ... has published over two hundred manuscripts in chemistry and religion, as well as four ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Glimpses Of ... understanding of the world. “Glimpses Of Light” is the creation of published author, J.M. ... life in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Although Labor Day ... July, many communities have begun providing weekend displays, and numerous households celebrate the unofficial ... they can be downright terrifying for pets. , Kris Zambo, owner of ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
Breaking Medicine Technology: